<DOC>
	<DOCNO>NCT00434278</DOCNO>
	<brief_summary>This multicenter , randomize , double-blind , placebo-controlled study patient severe , though stable , cystic fibrosis ( CF ) whose routine treatment include Pulmozyme . Patients randomize either continue Pulmozyme therapy withdrawn 2 week ( placebo group ) . Patients must stable CF symptom without change therapy 2 week prior enrollment order participate .</brief_summary>
	<brief_title>A Trial Pulmozyme Withdrawal Exercise Tolerance Cystic Fibrosis Subjects With Severe Lung Disease ( TOPIC )</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Signed Informed Consent Form , applicable , Assent Form Age ≥ 14 year old screen Proven diagnosis CF Ability perform acceptable reproducible spirometry maneuver screen FVC ≤ 45 % predict race , height , age , sex screen Chronic use Pulmozyme least 3 month last year daily twice daily use 14 day prior screen Stable regimen chest physiotherapy ( CPT ) least 14 day prior screen Ability complete 6minute walk test screen Ability complete 6minute walk test spirometry Visit 2 If routine tobramycin solution inhalation ( i.e. , TOBI® ) cycle antibiotic therapy , intention either start stop therapy time Visit 2 ( base routine therapy cycle ; plan change antibiotic regimen 28 day 28 day Visit 2 ) Clinically stable change medication 14 day prior screen Use investigational drug device within 28 day prior screen Previous episode acute respiratory failure require assist ventilation within 2 year prior screen Previous lung transplant Any cardiac disease would contraindicate perform 6minute walk test Pregnancy nurse Known hypersensitivity contraindication use Pulmozyme Previous completion premature discontinuation study drug withdrawal study More one prior screen failure study time prior screening failure study within last 28 day</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Lung disease</keyword>
	<keyword>CF</keyword>
	<keyword>Pulmozyme</keyword>
</DOC>